TY - JOUR AU - Garcia, Laura AU - Birckhead, Brandon AU - Krishnamurthy, Parthasarathy AU - Mackey, Ian AU - Sackman, Josh AU - Salmasi, Vafi AU - Louis, Robert AU - Castro, Carina AU - Maddox, Roselani AU - Maddox, Todd AU - Darnall, Beth D PY - 2022 DA - 2022/5/25 TI - 8周自我管理的基于家庭的虚拟现实治疗慢性腰痛效果的耐久性:背景:我们之前在一项双盲随机安慰剂对照研究中报道了一项为期8周的基于家庭的沉浸式虚拟现实(VR)治疗方案的疗效。自我报告慢性腰痛的社区成人以1:1的比例随机分配，接受(1)为期56天的沉浸式治疗性疼痛缓解技能VR项目(EaseVRx)或(2)为期56天的假VR项目。治疗后的即时结果显示，治疗性VR在减轻疼痛强度方面优于假性VR;与疼痛相关的活动、情绪和压力干扰(但不包括睡眠);生理功能;还有睡眠障碍。在治疗后3个月，治疗性VR在减轻疼痛强度和疼痛相关的活动、压力和睡眠干扰方面保持优势(新发现)。目的:本研究评估治疗后6个月的组间和组内治疗效果，以确定居家治疗性VR的延伸疗效、疗效大小和临床重要性。方法:在治疗前、治疗结束和治疗后1、2、3和6个月进行电子调查。 Self-reported data for 188 participants were analyzed in a mixed-model framework using a marginal model to allow for correlated responses across the repeated measures. Primary outcomes were pain intensity and pain-related interference with activity, mood, stress, and sleep at 6 months posttreatment. Secondary outcomes were Patient-Reported Outcome Measurement Information System (PROMIS) sleep disturbance and physical function. Results: Therapeutic VR maintained significant and clinically meaningful effects 6 months posttreatment and remained superior to sham VR for reducing pain intensity and pain-related interference with activity, stress, and sleep (ds=0.44-0.54; P<.003). Between-group comparisons for physical function and sleep disturbance showed superiority of EaseVRx over sham VR (ds=0.34; P=.02 and ds=0.46; P<.001, respectively). Participants were encouraged to contact study staff with any problems experienced during treatment; however, no participants contacted study staff to report adverse events of any type, including nausea and motion sickness. Conclusions: Our 8-week home-based VR pain management program caused important reductions in pain intensity and interference up to 6 months after treatment. Additional studies are needed in diverse samples. Trial Registration: ClinicalTrials.gov NCT04415177; https://clinicaltrials.gov/ct2/show/NCT04415177 International Registered Report Identifier (IRRID): RR2-10.2196/25291 SN - 1438-8871 UR - //www.mybigtv.com/2022/5/e37480 UR - https://doi.org/10.2196/37480 UR - http://www.ncbi.nlm.nih.gov/pubmed/35612905 DO - 10.2196/37480 ID - info:doi/10.2196/37480 ER -